Cara Therapeutics (CARA) Stock

STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “ Company ”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024.

Alessia's fans will experience a behind-the-scenes look at the creative process for her Love & Hyperbole album trailer through an episodic series, brought to life by Lenovo's smarter technology and Intel's cutting-edge processors. LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- In their sixth year of collaborating with globally-renowned artists to bring their creative visions to life, Lenovo, Intel, and Universal Music Group For Brands (UMGB), announced a new partnership with singer/songwriter and GRAMMY® Award-winning artist Alessia Cara.

Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases

NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cara Therapeutics, Inc. (NASDAQ: CARA ), relating to the proposed merger with Tvardi Therapeutics, Inc. Under the terms of the agreement, Cara Therapeutics stockholders are expected to own approximately 17.0% of the combined company.

Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.

Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo.

Cara Therapeutics (CARA) reported a quarterly loss of $0.56 per share, which was higher than the Zacks Consensus Estimate of a loss of $0.38 per share. This is compared to a loss of $0.49 per share in the same quarter last year.

Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.

Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2023 Earnings Call Transcript March 4, 2024 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Joana Goncalves - CMO Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Dennis Ding - Jefferies David Amsellem - Piper Sandler Operator Thank you for standing by, and welcome to Cara Therapeutics Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time all participants are in a listen-only mode.